All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Highlights from the first virtual COMy meeting
Bookmark this article
During COMy 2020, Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR, discussed highlights from the first virtual COMy meeting.
Professor Mohty outlined the controversial debates that took place during the virtual meeting. Debate topics included the treatment of elderly patients with multiple myeloma, the prognostic value of minimal residual disease to guide treatment decisions, and the routine incorporation of anti-CD38 monoclonal antibodies into induction regimens. A hot topic of the COMy 2020 online meeting was the question of whether or not to proceed with transplant, and professor Mohty concluded with a personal opinion on the matter.
Highlights from the first virtual COMy meeting
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox